ANAVEX 2-73 Advances Phase I Clinical Trial for Alzheimer’s Disease

Hoboken, NJ — May 23, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the first group of healthy human volunteers in the initial…